Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

March 23, 2024

Study Completion Date

January 31, 2025

Conditions

HealthySafety and Tolerability

Interventions

DRUG

DF-003

Oral administration by capsules (1 mg, 5 mg, or 25 mg).

DRUG

Placebo

Visually matching 0 mg DF-003 capsules.

Trial Locations (1)

Altasciences Clinical Los Angeles, Inc, Cypress

All Listed Sponsors

lead

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)

INDUSTRY

NCT05997641 - Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects | Biotech Hunter | Biotech Hunter